Milameline: Difference between revisions
Content deleted Content added
Reverted good faith edits by 86.23.68.198 (talk): Ref needed, will block account will checkuser takes place. (TW) |
Cats. |
||
| (27 intermediate revisions by 21 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| IUPAC_name = (''E'')-''N''-methoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine |
| IUPAC_name = (''E'')-''N''-methoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine |
||
| Line 7: | Line 8: | ||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| Line 13: | Line 14: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| IUPHAR_ligand = 301 |
|||
| CAS_number = 139886-32-1 |
| CAS_number = 139886-32-1 |
||
| ATC_prefix = None |
| ATC_prefix = None |
||
| Line 26: | Line 28: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=8 | H=14 | N=2 | O=1 |
| C=8 | H=14 | N=2 | O=1 |
||
| molecular_weight = 154.21 g/mol |
|||
| smiles = N(/OC)=C\C1=C\CCN(C)C1 |
| smiles = N(/OC)=C\C1=C\CCN(C)C1 |
||
}} |
}} |
||
'''Milameline''' ('''CI-979''', '''PD-129,409''', '''RU-35,926''') is a [[binding selectivity|non-selective]] [[muscarinic acetylcholine receptor]] [[partial agonist]] with [[cognition]]-acting properties that was being investigated for the treatment of [[Alzheimer's disease]], but produced poor results in [[clinical trial]]s and was subsequently discontinued.<ref name="pmid10188788">{{cite journal | |
'''Milameline''' ('''CI-979''', '''PD-129,409''', '''RU-35,926''') is a [[binding selectivity|non-selective]] [[muscarinic acetylcholine receptor]] [[partial agonist]] with [[cognition]]-acting properties that was being investigated for the treatment of [[Alzheimer's disease]], but produced poor results in [[clinical trial]]s and was subsequently discontinued.<ref name="pmid10188788">{{cite journal |vauthors=Sedman AJ, Bockbrader H, Schwarz RD | title = Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease | journal = Life Sciences | volume = 56 | issue = 11–12 | pages = 877–882 | year = 1995 | pmid = 10188788 | doi = 10.1016/0024-3205(95)00023-Y}}</ref> |
||
*Changing the ''O''-methyl aldoxime to an ''O''-[[propargyl]] oxime instead gives a separate molecule called [[RU 35986]].<ref name="BroadleyKelly2001">{{cite journal| vauthors = Broadley KJ, Kelly DR |title=Muscarinic Receptor Agonists and Antagonists |journal=Molecules |volume=6 |issue=3 |year=2001 |pages=142–193 |issn=1420-3049 |doi=10.3390/60300142 |pmc=6236374 |doi-access=free }}</ref> |
|||
== See also == |
== See also == |
||
| Line 41: | Line 44: | ||
{{Reflist}} |
{{Reflist}} |
||
{{Nootropics}} |
|||
{{Anti-dementia drugs}} |
{{Anti-dementia drugs}} |
||
{{Muscarinic acetylcholine receptor modulators}} |
|||
{{Cholinergics}} |
|||
[[Category: |
[[Category:Abandoned drugs]] |
||
[[Category: |
[[Category:Aldoximes]] |
||
[[Category: |
[[Category:M1 receptor agonists]] |
||
[[Category:M2 receptor agonists]] |
|||
[[Category:M3 receptor agonists]] |
|||
[[Category:M4 receptor agonists]] |
|||
[[Category:M5 receptor agonists]] |
|||
[[Category:Oxime ethers]] |
|||
[[Category:Tetrahydropyridines]] |
|||
Latest revision as of 04:37, 26 October 2024
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.220.595 |
| Chemical and physical data | |
| Formula | C8H14N2O |
| Molar mass | 154.213 g·mol−1 |
| 3D model (JSmol) | |
| |
Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.[1]
- Changing the O-methyl aldoxime to an O-propargyl oxime instead gives a separate molecule called RU 35986.[2]
See also
[edit]References
[edit]- ^ Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 877–882. doi:10.1016/0024-3205(95)00023-Y. PMID 10188788.
- ^ Broadley KJ, Kelly DR (2001). "Muscarinic Receptor Agonists and Antagonists". Molecules. 6 (3): 142–193. doi:10.3390/60300142. ISSN 1420-3049. PMC 6236374.